Skip to content

Physical Rehabilitation and Chronic Kidney Disease

Impact of Physical Rehabilitation on Sarcopenia Inolder and Chronic Kidney Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03671343
Acronym
IMPREPA
Enrollment
90
Registered
2018-09-14
Start date
2018-12-31
Completion date
2020-12-31
Last updated
2018-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Older, Sarcopenia

Keywords

sarcopenia, chronic kidney disease, older

Brief summary

Older patients with chronic renal failure suffer from sarcopenia. Loss of muscle function is associated with increased morbidity and mortality. Currently few treatment are available. The aim of this study is to evaluate the impact of physical rehabilitation in this population on muscle performance and quality of life.

Interventions

It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* man or woman * age over 70 years * CKD stage 3B, 4 or 5 or a DFG \<45ml / min according to CKD-EPI formula * an SPPB (Short Physical Performance Battery test )\<10 * having received a complete and loyal information and having given his written and informed consent. * ability to rehabilitate

Exclusion criteria

* Subject not presenting previous inclusion criteria * General condition not compatible for the realization of physical rehabilitation * Patient protected under the terms of the law. * Inability to respect the follow-up of the study for geographical, social or psychological reasons. * depression or other psychiatric disorder * Refusal to participate in the study * Absence of affiliation to the social security system * Subject in a exclusion period of an other study

Design outcomes

Primary

MeasureTime frame
Change from Baseline distance travelled (in meters) during the 6-minute walking distance (6MWD) test (muscular performance), at 3 monthsBaseline and 3 months

Secondary

MeasureTime frame
Nutritional parameter: PrealbuminemiaBaseline,3 and 6 months
Nutritional parameter: Body mass indexBaseline,3 and 6 months
Nutritional parameter: AlbuminemiaBaseline,3 and 6 months
Muscle strength evaluated by Hand Grip strength testBaseline,3 and 6 months
Quality of life evaluated by the questionnaire SF-36 (36-item medical outcomes study Short-Form health survey)Baseline,3 and 6 months
Nutritional parameter: bioimpedancemetryBaseline,3 and 6 months

Countries

France

Contacts

Primary ContactLaëtitia KOPPE, MD
laetitia.koppe@chu-lyon.fr0472678715

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026